Home › Cancer (all types) › NCT05376891

Met Non Small Cell Cancer Registry (MOMENT)

Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)

Who can join

All ages · All sexes

Inclusion Criteria:

* Participants who signed ICF
* Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
* Participants who are starting or are already being treated with systemic therapy

Exclusion Criteria:

* Participants who are enrolled in a clinical trial

About the study

The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.

The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.

Sponsor: EMD Serono Research & Development Institute, Inc. · Participants: 700 · Started: Oct 4, 2022

Contact the study team

• US Medical Information · Phone: 888-275-7376
• Communication Center · Phone: +49 6151 72 5200

Official record on ClinicalTrials.gov — NCT05376891

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.